Biotech Values

[ghmm]

AVXS:

That was a pretty poorly written report especially compared to some of their others. They reference a Seeking Alpha report which is more substantive (though I don't buy the short thesis of either). The least they could have done was attack RGNX (I'd like to take a position at a lower price).

To me the data will determine how the stock does more than anything. The $9 target in a few months doesn't seem data driven at all. If its real a GT would seem to me to be a very attractive option I agree with the camp that says if safety/efficacy good it would be first line and then possibly Nusinersen after. I am less concerned about enrolling patients for a P3 and some of the other things like the nonsense about NCH. I do think AVXS isn't cheap at this valuation and being their only therapy is quite risky (I would go with RGNX if one wanted to play the SMA GT at much lower risk and potentially more upside).